CN114269734B - Jak抑制剂 - Google Patents

Jak抑制剂

Info

Publication number
CN114269734B
CN114269734B CN202080050268.XA CN202080050268A CN114269734B CN 114269734 B CN114269734 B CN 114269734B CN 202080050268 A CN202080050268 A CN 202080050268A CN 114269734 B CN114269734 B CN 114269734B
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
compounds
formula
acceptable salt
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080050268.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN114269734A (zh
Inventor
拉朱·莫汉
约翰·努斯
詹森·哈里斯
袁沈东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vimaran Biosciences
Original Assignee
Vimaran Biosciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vimaran Biosciences filed Critical Vimaran Biosciences
Publication of CN114269734A publication Critical patent/CN114269734A/zh
Application granted granted Critical
Publication of CN114269734B publication Critical patent/CN114269734B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
CN202080050268.XA 2019-05-08 2020-05-07 Jak抑制剂 Active CN114269734B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962845119P 2019-05-08 2019-05-08
US62/845,119 2019-05-08
US201962884588P 2019-08-08 2019-08-08
US62/884,588 2019-08-08
PCT/US2020/031925 WO2020227563A1 (en) 2019-05-08 2020-05-07 Jak inhibitors

Publications (2)

Publication Number Publication Date
CN114269734A CN114269734A (zh) 2022-04-01
CN114269734B true CN114269734B (zh) 2026-03-27

Family

ID=73051620

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080050268.XA Active CN114269734B (zh) 2019-05-08 2020-05-07 Jak抑制剂

Country Status (13)

Country Link
US (1) US11136329B2 (enExample)
EP (1) EP3966209A4 (enExample)
JP (1) JP7617030B2 (enExample)
KR (1) KR102916168B1 (enExample)
CN (1) CN114269734B (enExample)
AU (1) AU2020267661B2 (enExample)
BR (1) BR112021022380A2 (enExample)
CA (1) CA3139277A1 (enExample)
IL (1) IL287876A (enExample)
MX (1) MX2021013602A (enExample)
SG (1) SG11202112362YA (enExample)
TW (1) TWI865525B (enExample)
WO (1) WO2020227563A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114269734B (zh) 2019-05-08 2026-03-27 维玛兰生物科学公司 Jak抑制剂
CA3150281A1 (en) 2019-08-08 2021-02-11 Vimalan Biosciences, Inc. Jak inhibitors
CN114644633B (zh) * 2020-12-18 2026-02-03 北京诺诚健华医药科技有限公司 杂环类jak抑制剂
KR102637915B1 (ko) * 2021-06-25 2024-02-19 한국화학연구원 유비퀴틴 프로테오좀 경로를 통해 비티케이 분해작용을 가지는 신규한 이작용성 헤테로사이클릭 화합물과 이의 용도
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ｃｋ１２抑制劑
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011134831A1 (en) * 2010-04-30 2011-11-03 Cellzome Limited Pyrazole compounds as jak inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801971A (zh) 2005-09-30 2010-08-11 沃泰克斯药物股份有限公司 可用作janus激酶抑制剂的脱氮嘌呤
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
AU2008211172A1 (en) 2007-01-30 2008-08-07 Biogen Idec Ma Inc. 1-H-pyrazolo(3,4B)pyrimidine derivatives and their use as modulators of mitotic kinases
UY31631A1 (es) 2008-02-06 2009-09-30 Nuevos derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino, sales de los mismos, procesos para su preparacion, composiciones farmacéuticas que los comprenden y aplicaciones
AU2009284098B2 (en) * 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
EA022120B1 (ru) * 2009-10-20 2015-11-30 Целльзом Лимитид Аналоги гетероциклил пиразолопиримидина в качестве ингибиторов jak
WO2011156698A2 (en) 2010-06-11 2011-12-15 Abbott Laboratories NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
WO2012143320A1 (en) * 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
KR20140063700A (ko) * 2011-09-20 2014-05-27 셀좀 리미티드 키나제 억제제로서의 피라졸로[4,3-c]피리딘 유도체
EA025186B1 (ru) 2012-06-29 2016-11-30 Пфайзер Инк. НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2
BR112017027951A2 (pt) 2015-06-22 2018-08-28 Ono Pharmaceutical Co., Ltd. composto inibitório de brk
CN108864057B (zh) * 2017-05-16 2020-03-31 山东大学 含有4-氨基吡唑结构的jak与hdac双靶点抑制剂及其制备方法和应用
CN114269734B (zh) 2019-05-08 2026-03-27 维玛兰生物科学公司 Jak抑制剂
CA3150281A1 (en) 2019-08-08 2021-02-11 Vimalan Biosciences, Inc. Jak inhibitors
EP4034107A4 (en) 2019-09-25 2023-08-30 Vimalan Biosciences, Inc. JAK INHIBITORS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011134831A1 (en) * 2010-04-30 2011-11-03 Cellzome Limited Pyrazole compounds as jak inhibitors

Also Published As

Publication number Publication date
BR112021022380A2 (pt) 2022-03-22
MX2021013602A (es) 2022-04-06
AU2020267661B2 (en) 2026-05-07
US20200369669A1 (en) 2020-11-26
EP3966209A1 (en) 2022-03-16
CA3139277A1 (en) 2020-11-12
JP2022532877A (ja) 2022-07-20
WO2020227563A1 (en) 2020-11-12
AU2020267661A1 (en) 2021-12-23
TW202108587A (zh) 2021-03-01
TWI865525B (zh) 2024-12-11
CN114269734A (zh) 2022-04-01
EP3966209A4 (en) 2023-01-04
IL287876A (en) 2022-01-01
US11136329B2 (en) 2021-10-05
KR20220052859A (ko) 2022-04-28
SG11202112362YA (en) 2021-12-30
JP7617030B2 (ja) 2025-01-17
KR102916168B1 (ko) 2026-01-21

Similar Documents

Publication Publication Date Title
CN113874021B (zh) Tyk2假激酶配体
JP7635228B2 (ja) Ｔｙｋ２偽キナーゼリガンド
TWI865525B (zh) Jak抑制劑
CN113677347A (zh) Tyk2假激酶配体
CA3076276A1 (en) 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof
CN115003300A (zh) Jak抑制剂
CN115038436A (zh) Jak抑制剂
HK40072097A (en) Jak inhibitors
HK40080624A (en) Jak inhibitors
HK40080028A (en) Tyk2 pseudokinase ligands
HK40064378A (en) Tyk2 pseudokinase ligands
HK40066192B (en) Tyk2 pseudokinase ligands
HK40066192A (zh) Tyk2假激酶配体
HK40080028B (en) Tyk2 pseudokinase ligands

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40072097

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant